Oncology

Nemvaleukin with and without pembrolizumab yielded promising anti-tumor activity and was well tolerated in patients with advanced solid tumors.

Neil M. Iyengar, MD, highlights the biggest advances in oncology, and where he expects the field to move next.

Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.

Identifying inefficiencies in the health care system, such as excessive regulations, highlights its impact on the oncology-based audience.

ASTRO assembled a task force to create a guideline for the administration of palliative external beam radiation therapy for patients with symptomatic bone metastases.

Performing ablation and injecting tumor sites with immunotherapy may be “synergistic”, according to Jason R. Williams, MD, DABR.

The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.

An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.

Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.

HER-directed treatment approaches in the tumor-agnostic field were the highlight of the discussion for a panel of experts who convened at WCLC 2024.

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Treatment with pimicotinib also yields meaningful improvements in stiffness and pain symptoms among patients with TGCT in the phase 3 MANEUVER study.

Patients who start smoking cessation treatment after cancer diagnosis are found to have higher rates of survival.

Phase 1 data support further assessment of DK210 (EGFR) in solid tumors such as renal cell carcinoma and non–small cell lung cancer.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

Julie M. Vose, MD, MBA, highlights the push toward gender diversity in medical oncology.

The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.

Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.

Major clinical trials lack documentation and participation data on Native Hawaiians and Pacific Islanders, a recent study finds.

Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.

Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.

cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.

Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.

STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.

STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.

Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.

Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.

Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.

Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.